Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Down - What's Next?

Key Points

• Hikma Pharmaceuticals' stock price gapped down significantly, opening at $23.96 after a previous close of $26.38, reflecting a drop of 9.2%.
• BNP Paribas has initiated coverage on Hikma Pharmaceuticals, with an "outperform" rating stated in a recent research note.
• The company's key financial metrics include a quick ratio of 0.65 and a current ratio of 1.14, indicating potential liquidity concerns.

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $26.38, but opened at $23.96. Hikma Pharmaceuticals shares last traded at $23.96, with a volume of 300 shares traded.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas initiated coverage on Hikma Pharmaceuticals in a research note on Tuesday, May 13th. They issued an "outperform" rating on the stock.

Hikma Pharmaceuticals Stock Performance

The business has a 50 day simple moving average of $27.14 and a 200-day simple moving average of $27.00. The company has a quick ratio of 0.65, a current ratio of 1.24 and a debt-to-equity ratio of 0.33.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.